Previous Close | 0.6929 |
Open | 0.7090 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.6630 - 0.7199 |
52 Week Range | 0.3900 - 2.0500 |
Volume | |
Avg. Volume | 4,118,050 |
Market Cap | 684.052M |
Beta (5Y Monthly) | 0.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0630 |
Earnings Date | Aug 08, 2020 - Aug 12, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for NWBO
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made today at 11:10 a.m., at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences. The presentation will be made by Dr. Paul Mulholland of University College Hospital.
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK.